Literature DB >> 31421633

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

Yali Sang1, Sheng Han1, Christophe Pannecouque2, Erik De Clercq2, Chunlin Zhuang3, Fener Chen4.   

Abstract

Conformational restriction is a promising strategy in the development of DAPY-type non-nucleoside reverse transcriptase inhibitors (NNRTIs). Herein, eighteen thiophene-biphenyl-DAPY derivatives were designed and synthesized as potent HIV-1 NNRTIs in which halogen and methyl groups were introduced to explore the conformationally constrained effects. Molecular docking and dynamic simulation analysis indicated that substituents on different positions of the biphenyl ring induced different dihedral angles and binding conformations, further explaining their anti-viral activities. The 2'-fluoro and 3'-chloro substitutions could form electrostatic or halogen-bonding interactions with adjacent residues of the RT enzyme. The 2'-methyl group contributed to enlarge the dihedral angle of biphenyl ring and was positioned to a space-filling hydrophobic pocket. Notably, compounds 22 and 23 with two methyl groups exhibited potent biological activity against WT HIV-1-infected MT-4 cells (EC50 = 14 and 17 nM, respectively) and RT enzyme (EC50 = 27 and 42 nM, respectively). In particular, 23 exhibited much lower cytotoxicity (CC50 = 264.19 μM) and higher selectivity index (SI = 18,564) than etravirine. Taken together, a rational conformational model for further design of DAPYs is proposed, providing a new guidance for the development of NNRTIs.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biphenyl-DAPY; Conformational restriction; HIV-1; Molecular modeling; NNRTIs

Mesh:

Substances:

Year:  2019        PMID: 31421633     DOI: 10.1016/j.ejmech.2019.111603

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs.

Authors:  Ting-Ting Li; Christophe Pannecouque; Erik De Clercq; Chun-Lin Zhuang; Fen-Er Chen
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

2.  Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Kaijun Jin; Minjie Liu; Chunlin Zhuang; Erik De Clercq; Christophe Pannecouque; Ge Meng; Fener Chen
Journal:  Acta Pharm Sin B       Date:  2019-10-17       Impact factor: 11.413

3.  Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Authors:  Yuan Lei; Sheng Han; Yang Yang; Christophe Pannecouque; Erik De Clercq; Chunlin Zhuang; Fen-Er Chen
Journal:  Molecules       Date:  2020-02-26       Impact factor: 4.411

Review 4.  Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents.

Authors:  Prisca Lagardère; Cyril Fersing; Nicolas Masurier; Vincent Lisowski
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.